Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 44Lymphoma, Follicular 28Lymphoma, Mantle-Cell 27Leukemia, Lymphocytic, Chronic, B-Cell 27Lymphoma 26Lymphoma, Non-Hodgkin 24Lymphoma, B-Cell, Marginal Zone 16Lymphoma, B-Cell 14Recurrence 12Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms 9Waldenstrom Macroglobulinemia 8Leukemia, Hairy Cell 5Lymphoproliferative Disorders 4Leukemia 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Hodgkin Disease 3Hematologic Neoplasms 3beta-Thalassemia 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Lymphatic Diseases 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Leukemia, B-Cell 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2

Interventions

Cyclophosphamide 15venetoclax 11fludarabine 10Cytarabine 10Mycophenolic Acid 6Azacitidine 6fludarabine phosphate 5Daunorubicin 5Busulfan 5ruxolitinib 4ponatinib 4blinatumomab 4Whole-Body Irradiation 4Vincristine 4Tacrolimus 4Rituximab 4Methotrexate 4Dexamethasone 4asciminib 3Mercaptopurine 3Inotuzumab Ozogamicin 3Granulocyte Colony-Stimulating Factor 3Cyclosporine 3revumenib 2quizartinib 2pegaspargase 2nilotinib 2ibrutinib 2Thioguanine 2Prednisone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Leukemia × Rituximab × 90 days × Clear all
NCT01446133 2026-05-22

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
120 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05645718 2026-05-19

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
27 enrolled
Other hematologic neoplasm

Leukemia

NCT03467867 2026-04-06

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Georgetown University

Phase 2 Active not recruiting
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoproliferative Disorders, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07294677 2026-03-04

CAVALRY

University of Chicago

Phase 1/2 Recruiting
104 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡